inclusion criteria: * a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation * men and women aged ≥ 25 - 80 (included) years of age * hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline * hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>2l per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure * confirmed infection with covid-19 by any acceptable test available/utilized at each site * private insurance or government support (through nhs or other)

inclusion criteria: * a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation * men and women aged ≥ 25 - 80 (included) years of age * hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline * hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>2l per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure * confirmed infection with covid-19 by any acceptable test available/utilized at each site * private insurance or government support (through nhs or other)

inclusion criteria: - a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation - men and women aged ≥ 25 - 80 (included) years of age - hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline - hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >2l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure - confirmed infection with covid-19 by any acceptable test available/utilized at each site - private insurance or government support (through nhs or other)

inclusion criteria: - a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation - men and women aged ≥ 25 - 80 (included) years of age - hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline - hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >2l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure - confirmed infection with covid-19 by any acceptable test available/utilized at each site - private insurance or government support (through nhs or other)

inclusion criteria: - a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation - men and women aged ≥ 25 - 80 (included) years of age - hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline - hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure - confirmed infection with covid-19 by any acceptable test available/utilized at each site - private insurance or government support (through nhs or other)

inclusion criteria: - a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation - men and women aged ≥ 25 - 80 (included) years of age - hospitalized patients with one absolute lymphocyte count (alc) ≤ 1000 cells/mm3, collected at baseline or no more than 72h before baseline - hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure - confirmed infection with covid-19 by any acceptable test available/utilized at each site - private insurance or government support (through nhs or other)

inclusion criteria: - a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation - men and women aged ≥ 25 - 80 (included) years of age - hospitalized patients with two absolute lymphocyte count (alc) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following hospitalization: the first time point should not be performed earlier than 48 hours after hospitalization, thus first test dose can't be administered before 72 hours after hospitalization (from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status) - hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure - confirmed infection with covid-19 by any acceptable test available/utilized at each site - private insurance or government support (through nhs or other)

inclusion criteria: - a written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing study participation - men and women aged ≥ 25 - 80 (included) years of age - hospitalized patients with two absolute lymphocyte count (alc) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following hospitalization: the first time point should not be performed earlier than 48 hours after hospitalization, thus first test dose can't be administered before 72 hours after hospitalization (from this time point the investigator may choose to further postpone the commencement of il-7 (cyt107) treatment according to patient's clinical status) - hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4l per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., bipap), or patients intubated/ventilated for respiratory failure - confirmed infection with covid-19 by any acceptable test available/utilized at each site - private insurance or government support (through nhs or other)